Vir Biotechnology, Inc. Common Stock
Here’s whether Vir Biotechnology, Inc. Common Stock (VIR) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); strong 1-year return of +50.9%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.89% over 10 days); RSI 26 — oversold; 3-month momentum negative (-16.2%). Currently 25.5% off its 52-week high. Score: -1/7.
VIR is holding above its long-term 200-day MA ($7.99) but has slipped below the 50-day MA ($9.32), pointing to short-term weakness in an otherwise intact trend. An RSI of 26.5 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +50.9% compares to +16.5% for SPY (beat the market by 34.4%). The current 25.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.